MedDataX Logo

Impact of Human Papillomavirus Carriage on IVF/ICSI Results (HPV AMP)

NCT ID: NCT06550531

Last Updated: 2024-08-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

618 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-02-04

Study Completion Date

2026-02-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The prevalence of the papilloma virus in the general population is 12%. This virus is known to impair male fertility but its impact on female infertility remains uncertain. This is a public health problem since there is a vaccination protocol. Demonstrating the impact of the human papillomavirus on fertility would be an argument in favor of vaccination.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation

NCT01894425

Infertility Sub-fertility Papillomavirus Infections
COMPLETED

Prevalence of HPV Transmission During Medically Assisted Procreation Procedures

NCT02524223

Human Papillomavirus (HPV) Medically Assisted Procreation (MAP) Infertility
COMPLETED NA

Impact of HPV Vaccination on Cervical High Grade Lesions in France

NCT04167501

Human Papillomavirus Infection
COMPLETED

Negative HPV Test Results on Infinity/GeneXpert® With the Presence of a Late Amplification Signal: What Does This Mean ? (PaPCR)

NCT06919627

Cervical Cancers Papillomavirus Infections Papillomavirus Type 16/18 Infection
RECRUITING

Infectious Risk of Vaginal Ultrasound Examination: Evaluation and Modeling From Human Papillomavirus (HPV)

NCT02659072

GYNAECOLOGICAL INFECTION
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single-center prospective study in the assisted reproduction center of Brest University Hospital. All new patients coming to consult will be offered participation in the study. The HPV test will be updated if it is older than 12 months. We will analyze stimulation results and pregnancy outcomes according to HPV status. Inclusions will take place over 3 years

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Human Papilloma Virus Infertility, Female

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all etiology of infertility AMH \> ou = à 1.1 ng/ml First ou second protocol of IVF between 25 years and 37 years and 11 months

Exclusion Criteria

Age \< 25 y Age \> ou = 38 y AMH \< 1.1 ng/ml patient under juridic protection rejection of participation
Minimum Eligible Age

25 Years

Maximum Eligible Age

38 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Brest

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHRU de Brest

Brest, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sarah BOUEE

Role: CONTACT

[email protected]
02 98 22 39 70

Anne-Solenn JACAMON

Role: CONTACT

[email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sarah BOUEE

Role: primary

[email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

29BRC21.0363 - HPV AMP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Urinary Human Papilloma Virus Test in the General Population in Brittany
NCT03598946 UNKNOWN NA
Impact of Catch-up HPV Vaccination
NCT05462249 TERMINATED
Multimodality Treatments of HPV-related Lesions of the Female Genital Tract
NCT05938192 RECRUITING
Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring
NCT05774561 RECRUITING NA
Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination in Integrated Healthcare Delivery Systems
NCT03887793 WITHDRAWN NA
Human Papillomavirus and Cervical Dysplasia in Women With Cystic Fibrosis
NCT03052556 COMPLETED NA
Agreement Between Oral and Cervical Human Papillomavirus Infection in a French Cohort
NCT02774538 COMPLETED NA
Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer
NCT00435214 COMPLETED
SUCCESS - Feasibility of HPV Testing and Treatment of Pre-cancerous Cervical Cancer Lesions (HPV Study)
NCT05133661 ACTIVE_NOT_RECRUITING
Colposcopic Impression in a Birth Cohort Previously Eligible for HPV-vaccination
NCT04909814 COMPLETED
Use of Human Papillomavirus Persistence for Determination of Treatment Efficacy Among Women With Cervical Dysplasia
NCT00931190 COMPLETED
Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention
NCT01014026 COMPLETED PHASE3
Impact of HPV Vaccination to Catch up in the Emergence of Lesions of the Cervix
NCT03328013 TERMINATED
Epidemiology of Papillomavirus Infection (HPV) on Infected Women by Human Immunodeficience Virus (HIV) in West Indies and French Guiana.
NCT01226368 COMPLETED
Multi-site HPV Screening by High-throughput Sequencing in Patients With Chronic HPV-HR Infection Followed by Gynecology
NCT04901351 RECRUITING NA
Prognostic Study of HPV Virus Integration in Women With HSIL
NCT05745597 RECRUITING
A Cohort Study for the Following up of Conization
NCT03961178 UNKNOWN
Evaluation of Initial High Risk Human Papillomavirus (HR-HPV) Viral Load as Predictive Marker for Cervical Intraepithelial Neoplasia Grade 1 (CIN1) Persistence
NCT00682552 TERMINATED NA
HPV Infections, Cancer of the Vulva and Therapeutical Success
NCT03082950 COMPLETED
Research About Impact of HPV Integration on the Prognosis of Women With Persistent HR-HPV Infection
NCT05283239 RECRUITING
Evaluation of Prevalence of Sexuality Alteration in Women With an Abnormal Pap Test
NCT05701020 COMPLETED NA
Prevalence, Persistence, and Risk Factors for Oral Human Papillomavirus (HPV) Infections in College Women
NCT01289873 COMPLETED
Anal Follow-up of Patients With a Gynecological History of High-grade Lesion and More Induced HPV
NCT05566106 RECRUITING
Vaginal Self-sampling for Detecting High-risk Human Papillomavirus Cervical Infection in Patients With Immune-mediated Inflammatory Diseases
NCT06302725 ACTIVE_NOT_RECRUITING NA
Multiple Human Papillomavirus Infections in the Development of CIN
NCT06862102 RECRUITING